Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL056 vs alendronate in postmenopausal osteoporosis (phase III)
ChiCTR2200057843Phase 3Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Xinfutai in osteoporosis (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Rate of change in lumbar spine (L1–L4) bone mineral density from baseline. Started Jun 2021; status: recruiting.
02
Drugs
Xinfutai
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2200057843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057843.